Predictive testing in non-small cell lung carcinoma.

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Research

Background:

• Predictive testing is essential for non-small cell lung cancer (NSCLC) treatment decisions.
• Rapid advancements in diagnostics and therapeutics necessitate updated guidelines for optimal care.
• Evolving molecular markers require continuous evaluation in routine practice.

Purpose of the Study:

• To offer a comprehensive overview of predictive testing challenges in NSCLC at the molecular level.
• To evaluate PD-L1 expression based on international and national guidelines.
• To summarize the current status of predictive testing for NSCLC in the Czech Republic.

Main Methods:

• Review of current international and national guidelines for NSCLC predictive testing.
• Analysis of molecular marker testing strategies, including PD-L1 evaluation.
• Assessment of diagnostic approaches in the context of the Czech Republic's healthcare system.

Main Results:

• Predictive testing is integral to NSCLC diagnostics and treatment planning.
• Sequential marker testing is becoming insufficient due to the expanding range of predictors.
• Next-generation sequencing (NGS) presents a more suitable solution for complex molecular profiling.

Conclusions:

• Predictive testing in NSCLC is a dynamic field requiring adaptation.
• NGS is recommended for comprehensive molecular testing over sequential approaches.
• Immunohistochemical assessment of PD-L1 expression remains a critical component of NSCLC predictive testing.